Myriad Genetics (MYGN) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.03 per share a year ago. These figures ...
SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Myriad Genetics Inc. (MYGN) on Thursday reported a loss of $22.1 million in its third quarter. On a per-share basis, the Salt Lake City-based company said ...
Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
The company is scheduled to hold its third quarter 2024 earnings conference call after the market closes on Thursday November 7, 2024, and intends to provide additional information regarding its ...
The industry is now watching to see how this development will shape the company's financial outlook and whether other insurers will follow UNH's lead. In other recent news, Myriad Genetics has ...
The market's response to the news has been notably negative, but it remains to be seen whether the current drop in Myriad Genetics' stock price is an overreaction or an accurate reflection of the ...
Myriad Genetics (NASDAQ:MYGN) is down ~20% in Friday trading following reports that UnitedHealth Group (UNH) will no longer cover the company's genetic test that helps to determine which mental ...